Swedbank AB Has $355.13 Million Position in Zoetis Inc. $ZTS

Swedbank AB boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 9.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,004,200 shares of the company’s stock after acquiring an additional 269,610 shares during the quarter. Swedbank AB’s holdings in Zoetis were worth $355,126,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP raised its holdings in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. State Street Corp lifted its stake in shares of Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after purchasing an additional 149,382 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after purchasing an additional 189,235 shares during the last quarter. Finally, Norges Bank bought a new stake in Zoetis in the fourth quarter worth $734,425,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of Zoetis stock traded up $0.74 during trading on Tuesday, reaching $76.16. The company’s stock had a trading volume of 1,501,364 shares, compared to its average volume of 5,618,771. Zoetis Inc. has a one year low of $71.47 and a one year high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a market cap of $31.93 billion, a price-to-earnings ratio of 12.63, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75. The business’s fifty day moving average price is $84.04 and its 200-day moving average price is $109.31.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Insider Transactions at Zoetis

In related news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ZTS. Citigroup lowered their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. UBS Group decreased their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Barclays lowered their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Stifel Nicolaus cut their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Finally, Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $123.46.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.